25-羟基维生素D清除率随eGFR和种族差异的药代动力学研究
该药代动力学研究对87名成人(正常eGFR、非透析CKD、血液透析ESKD)静脉给予氘代25(OH)D3,计算清除率。结果显示25(OH)D清除率随eGFR降低而减少,黑人种族在正常eGFR者中清除率更高,但CKD或肾衰竭者中无此差异,维生素D3补充前后清除率无差异。
要点
- CKD和肾衰竭患者25(OH)D清除率降低,且与eGFR下降独立相关。
- 黑人种族仅在正常eGFR者中与较高25(OH)D清除率相关。
- 口服维生素D3补充不改变25(OH)D清除率。
核心结论
- 直接药代动力学测量显示CKD患者25(OH)D清除率降低,且可能因种族而异。
研究设计与样本
- 药代动力学研究,纳入87名成人:43例eGFR≥60 ml/min per 1.73 m2,24例非透析CKD(eGFR<60 ml/min per 1.73 m2),20例血液透析ESKD。
- 静脉给予氘代25(OH)D3,于5分钟、4小时及1、4、7、14、21、28、42、56天测量浓度,用非房室分析计算清除率。
- 18名参与者在延长口服维生素D3补充后重复测量清除率。
主要发现
- 平均25(OH)D清除率在正常eGFR、CKD和肾衰竭组分别为360 ml/d、313 ml/d和263 ml/d(P=0.02)。
- 调整年龄、性别、种族和估计血容量后,eGFR每降低10 ml/min per 1.73 m2,25(OH)D清除率减少17 ml/d(β=-17 ml/d;95% CI,-21至-12)。
- 黑人种族在正常eGFR参与者中与较高25(OH)D清除率相关,但在CKD或肾衰竭者中不相关(交互P=0.05)。
- 维生素D3补充前后25(OH)D清除率无差异。
临床怎么用
- 临床评估维生素D状态时需考虑肾功能对25(OH)D清除的影响。
- 黑人种族与25(OH)D清除率的关联受肾功能影响,解读维生素D水平时应结合eGFR和种族。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conversion of 25-hydroxyvitamin D (25[OH]D) to the active form of vitamin D occurs primarily in the kidney. Observational studies suggest 25(OH)D clearance from the circulation differs by kidney function and race. However, these potential variations have not been tested using gold-standard methods. METHODS: We administered intravenous, deuterated 25(OH)D3 (d-25[OH]D3) in a pharmacokinetic study of 87 adults, including 43 with normal eGFR (≥60 ml/min per 1.73 m2), 24 with nondialysis CKD (eGFR <60 ml/min per 1.73 m2), and 20 with ESKD treated with hemodialysis. We measured concentrations of d-25(OH)D3 and deuterated 24,25-dihydroxyvitamin D3 at 5 minutes and 4 hours after administration, and at 1, 4, 7, 14, 21, 28, 42, and 56 days postadministration. We calculated 25(OH)D clearance using noncompartmental analysis of d-25(OH)D3 concentrations over time. We remeasured 25(OH)D clearance in a subset of 18 participants after extended oral vitamin-D3 supplementation. RESULTS: The mean age of the study cohort was 64 years; 41% were female, and 30% were Black. Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02). After adjustment for age, sex, race, and estimated blood volume, lower eGFR was associated with reduced 25(OH)D clearance (β=-17 ml/d per 10 ml/min per 1.73 m2 lower eGFR; 95% CI, -21 to -12). Black race was associated with higher 25(OH)D clearance in participants with normal eGFR, but not in those with CKD or kidney failure (P for interaction=0.05). Clearance of 25(OH)D before versus after vitamin-D3 supplementation did not differ. CONCLUSIONS: Using direct pharmacokinetic measurements, we show that 25(OH)D clearance is reduced in CKD and may differ by race. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease (CLEAR), NCT02937350; Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation (CLEAR-PLUS), NCT03576716.
引用
- Hsu S, Zelnick LR, Lin YS, et al. Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. J Am Soc Nephrol. 2020. PMID: 33115916. doi:10.1681/ASN.2020050625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。